R-Pharm

R-Pharm logo

R-Pharm (Russian: Р-Фарм) is an international pharmaceutical company headquartered in Russia.[1][2][3][4][5][6] It reached the headlines in September 2020 following approval of its drug "Coronavir" as a treatment in cases of mild to moderate COVID-19 infection.[7][8] It was founded by Alexey Repik (ru) in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017.[9] In 2022, against the background of the introduction of personal sanctions, Alexey Repik resigned from the owners of R-Pharm, selling his share in the company to the management of R-Pharm, and resigned as chairman of the board of directors [1].

  1. ^ "About company История Компании (History of R-Pharm)". r-pharm.com.[dead link]
  2. ^ "R-Pharm". www.weforum.org. Retrieved 23 June 2021.
  3. ^ "R-Pharm ZAO - Company Profile and News". Bloomberg.com. Retrieved 23 June 2021.
  4. ^ "О КОМПАНИИ ГК «Р-Фарм» – российская высокотехнологичная фармацевтическая компания полного производственного цикла" [ABOUT: R-Pharm Group of Companies is a Russian high-tech pharmaceutical company with a full production cycle]. archive.wikiwix.com. Retrieved 23 June 2021.
  5. ^ "Р-Фарм". www.r-pharm.com. Retrieved 29 November 2023.
  6. ^ "Рейтинг крупнейших компаний России по объему реализации продукции* (archived copy)" [Rating of the largest Russian companies in terms of product sales]. archive.wikiwix.com. Retrieved 23 June 2021.
  7. ^ Cite error: The named reference ReuterFr was invoked but never defined (see the help page).
  8. ^ "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters. 18 September 2020. Archived from the original on 18 July 2023. Retrieved 18 July 2023.
  9. ^ "Herbert Smith Freehills advises Mitsui on strategic acquisition of a 10% interest in Russia's R-Pharm". Herbert Smith Freehills | Global law firm. 28 April 2017. Retrieved 28 November 2023.